| First Author | Sack U | Year | 2011 |
| Journal | Mol Biol Cell | Volume | 22 |
| Issue | 18 | Pages | 3344-54 |
| PubMed ID | 21795396 | Mgi Jnum | J:183025 |
| Mgi Id | MGI:5317362 | Doi | 10.1091/mbc.E10-09-0739 |
| Citation | Sack U, et al. (2011) S100A4-induced cell motility and metastasis is restricted by the Wnt/beta-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell 22(18):3344-54 |
| abstractText | The calcium-binding protein S100A4 is a central mediator of metastasis formation in colon cancer. S100A4 is a target gene of the Wnt/beta-catenin pathway, which is constitutively active in the majority of colon cancers. In this study a high-throughput screen was performed to identify small-molecule compounds targeting the S100A4-promoter activity. In this screen calcimycin was identified as a transcriptional inhibitor of S100A4. In colon cancer cells calcimycin treatment reduced S100A4 mRNA and protein expression in a dose- and time-dependent manner. S100A4-induced cellular processes associated with metastasis formation, such as cell migration and invasion, were inhibited by calcimycin in an S100A4-specific manner. Calcimycin reduced beta-catenin mRNA and protein levels despite the expression of Delta45-mutated beta-catenin. Consequently, calcimycin inhibited Wnt/beta-catenin pathway activity and the expression of prominent beta-catenin target genes such as S100A4, cyclin D1, c-myc, and dickkopf-1. Finally, calcimycin treatment of human colon cancer cells inhibited metastasis formation in xenografted immunodeficient mice. Our results demonstrate that targeting the expression of S100A4 with calcimycin provides a functional strategy to restrict cell motility in colon cancer cells. Therefore calcimycin may be useful for studying S100A4 biology, and these studies may serve as a lead for the development of treatments for colon cancer metastasis. |
